TY - JOUR
T1 - The Use of alendronate is associated with a decreased incidence of type 2 diabetes mellitus - A population-based cohort study in Taiwan
AU - Chan, Ding Cheng
AU - Yang, Rong Sen
AU - Ho, Chung Han
AU - Tsai, Yau Sheng
AU - Wang, Jhi Joung
AU - Tsai, Kang Ting
N1 - Publisher Copyright:
© 2015 Chan et al.
PY - 2015/4/13
Y1 - 2015/4/13
N2 - Purpose: Bone remodeling has been linked to glucose metabolism in animal studies, but the results of human trials were inconclusive. Bisphosphonates may play a role in glucose metabolism through their impacts on bone remodeling enzymes. In this study, we aimed to examine the influence of alendronate usage on the incidence of type 2 diabetes mellitus (DM) among osteoporotic patients. Methods: A retrospective cohort study was designed to include osteoporotic patients without DM from a population-based cohort containing 1,000,000 subjects. Patients treated with alendronate (exposed group, N=1,011) were compared with those who received no treatment (age and gender matched non-exposed group, N=3,033). Newly diagnosed DM was identified from medical records by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9CM) code. The incidence of DM in both groups was calculated for comparison. Results: The non-exposed group had a significantly higher incidence of DM (Odds ratio 1.21, 95% confidence interval 1.03-1.41) when compared with the exposed group. In subgroup analysis, the DM risk reduction in exposed group was only significant among those younger than 65 years and thosewithout hypertension or dyslipidemia. Patients who were prescribed alendronate more than or equal to 3 times had demonstrated a significant reduction in DM risk. Conclusions: Our study showed alendronate might yield a protective effect for incident DM. This effect became insignificant in patients with older age, dyslipidemia or hypertension. The underlying mechanism needs further exploration with prospective data for confirmation of the observed findings.
AB - Purpose: Bone remodeling has been linked to glucose metabolism in animal studies, but the results of human trials were inconclusive. Bisphosphonates may play a role in glucose metabolism through their impacts on bone remodeling enzymes. In this study, we aimed to examine the influence of alendronate usage on the incidence of type 2 diabetes mellitus (DM) among osteoporotic patients. Methods: A retrospective cohort study was designed to include osteoporotic patients without DM from a population-based cohort containing 1,000,000 subjects. Patients treated with alendronate (exposed group, N=1,011) were compared with those who received no treatment (age and gender matched non-exposed group, N=3,033). Newly diagnosed DM was identified from medical records by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9CM) code. The incidence of DM in both groups was calculated for comparison. Results: The non-exposed group had a significantly higher incidence of DM (Odds ratio 1.21, 95% confidence interval 1.03-1.41) when compared with the exposed group. In subgroup analysis, the DM risk reduction in exposed group was only significant among those younger than 65 years and thosewithout hypertension or dyslipidemia. Patients who were prescribed alendronate more than or equal to 3 times had demonstrated a significant reduction in DM risk. Conclusions: Our study showed alendronate might yield a protective effect for incident DM. This effect became insignificant in patients with older age, dyslipidemia or hypertension. The underlying mechanism needs further exploration with prospective data for confirmation of the observed findings.
UR - http://www.scopus.com/inward/record.url?scp=84928885474&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928885474&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0123279
DO - 10.1371/journal.pone.0123279
M3 - Article
C2 - 25874962
AN - SCOPUS:84928885474
SN - 1932-6203
VL - 10
JO - PloS one
JF - PloS one
IS - 4
M1 - e0123279
ER -